The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse

Abstract

Lacidipine has anti-atherogenic effects in the apoE-deficient mouse, and reduces plasma endothelin concentrations.

Calcium Channel Blocker Inhibits Western-Type Diet-Evoked Atherosclerosis Development in ApoE-Deficient Mice

“…They concluded that the antiatherosclerotic effect of lacidipine seems independent of the blood pressure-lowering effect. This conclusion was in agreement with Cristofori et al (2000) who reported that lacidipine reduces the development of atherosclerotic lesions in female ApoE-deficient mice that were fed a normal chow.…”

“…The purpose of the present experiments was to test the hypothesis proposed by Cristofori et al (2000) that it is unlikely that the antiatherosclerotic properties of lacidipine could be related to the well known antihypertensive effect of the drug, because the dosage they used (3.0 mg/kg/day) did not affect blood pressure values in ApoE-deficient mouse. Indeed, lacidipine has an antioxidant capacity comparable with vitamin E (van Amsterdam et al, 1992), and the dose of 3.0 mg/kg/day seems to be bioequivalent as antioxidant to the amount of vitamin E supplemented by Pratico et al (1998) in ApoE KO mice that were fed a normal diet.…”

Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis

“…21,22 Lacidipine has been shown to reduce the development of atherosclerotic lesions in the nondiabetic apoE-null mouse. 10 In the hyperlipidemic nondiabetic hamster, amlodipine limited the size and extent of atherosclerotic plaque. 23 However, although irbesartan and another calcium channel blocker, lacidipine, have been shown to reduce plaque size in the nondiabetic apoE-null mouse, 8,10 amlodipine failed to reduce plaque area in the diabetic context.…”

“…10 In the hyperlipidemic nondiabetic hamster, amlodipine limited the size and extent of atherosclerotic plaque. 23 However, although irbesartan and another calcium channel blocker, lacidipine, have been shown to reduce plaque size in the nondiabetic apoE-null mouse, 8,10 amlodipine failed to reduce plaque area in the diabetic context. Diabetes-induced accelerated plaque formation in the aorta of the diabetic apoE-null mice was associated with a significant increase in collagen content, infiltration of vascular smooth muscle cells and macrophages, and cellular proliferation.…”

Targeted Deletion of Angiotensin II Type 1A Receptor Does not Protect Mice from Progressive Nephropathy of Overload Proteinuria

“…AT 1A ϩ/ϩ (n ϭ 11) and AT 1A Ϫ/Ϫ (n ϭ 7) mice received daily intraperitoneal injections of BSA (10 mg/g) and were killed at 11 wk. For ruling out that possible difference in renal injury between BSA-treated AT 1A ϩ/ϩ and AT 1A Ϫ/Ϫ mice could be due to the different BP levels previously reported in the two strains (14), an additional group of AT 1A ϩ/ϩ (n ϭ 7) mice were treated daily with the dihydropyridinic calcium channel blocker lacidipine (3 mg/kg) by gavage (19). AT 1A ϩ/ϩ (n ϭ 6) and AT 1A Ϫ/Ϫ (n ϭ 6) mice that received saline were followed for 11 wk and used as controls.…”